Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients
December 2018
in “
JAMA Surgery
”
New to Spironolactone? There is a guide in the encyclopedia. Read the guide →
Studysummary This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer